
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp is positioned for a positive financial outlook, primarily due to strong growth projections for its MACI product, which is expected to see volume increases in the low-to-mid teens, along with annual average selling price (ASP) growth of 300 to 500 basis points. Projections for fiscal year 2026 estimate MACI's top-line revenue growth in the high teens to low 20s range, aligning with overall market expectations of approximately 21.2% year-over-year growth. Additionally, the anticipated revenue for the fourth quarter reflects a notable increase of 26% quarter-over-quarter, indicating solid momentum heading into the new fiscal year.
Bears say
Vericel Corp's outlook is negatively impacted by lowered revenue expectations for its MACI product in fiscal years 2026 and 2027, with a reduction of approximately 200 basis points. Additionally, there are significant risks related to slower uptake of the MACI Arthro, potential declines in burn care sales, and disruptions associated with the expansion of the sales force. If Vericel fails to meet top-line expectations in upcoming quarters, it is anticipated that the company's shares could decline to historical low valuation levels.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares